This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The dataset analyzed in this study is available from the corresponding author upon reasonable request.
References
Bazarbachi A-H, Reef D, Narvel H, Patel R, Al Hamed R, Vikash S, et al. Outcome of Stem Cell Transplantation in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma. Clin Hematol Int. 2023;5:78–91.
Utsunomiya A. Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma. Front Microbiol. 2019;10:2235.
Nosaka K, Iwanaga M, Imaizumi Y, Ishitsuka K, Ishizawa K, Ishida Y, et al. Epidemiological and clinical features of adult T-cell leukemia–lymphoma in Japan, 2010–2011: A nationwide survey. Cancer Sci. 2017;108:2478–86.
Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transpl. 2016;51:205–11.
Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, et al. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. Bone Marrow Transpl. 2021;56:155–66.
Tanaka T, Nakamae H, Ito A, Fuji S, Hirose A, Eto T, et al. A Phase I/II Multicenter Trial of HLA-Haploidentical PBSCT with PTCy for Aggressive Adult T Cell Leukemia/Lymphoma. Transplant Cell Ther. 2021;27:928.e1–e7.
Ito A, Nakano N, Tanaka T, Fuji S, Makiyama J, Inoue Y, et al. Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study. Blood Adv. 2021;5:4156–66.
Hishizawa M, Kanda J, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood. 2010;116:1369–76.
Ishii K, Okamoto S, Fujita M, Sugihara A, Nagaie T, Nishioka A, et al. [HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide for adult T-cell leukemia]. Rinsho Ketsueki. 2022;63:333–40.
Yoshimitsu M, Utsunomiya A, Fuji S, Fujiwara H, Fukuda T, Ogawa H, et al. A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia–lymphoma. Bone Marrow Transpl. 2019;54:1266–74.
Bashey A, Zhang M-J, McCurdy SR, Martin AS, Argall T, Anasetti C, et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell–Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017;35:3002.
Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, et al. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. JCO. 2016;34:3426–33.
Acknowledgements
This work was supported by a grant from the Japan Society for the Promotion of Science (JSPS; KAKENHI Grant number 23K06746) and the Project Mirai Cancer Research Grants.
Author information
Authors and Affiliations
Contributions
AH, HK, and HN contributed to the conceptualization and design of the study. AH and MNa collected and cleaned data. AH, HK, KI analyzed the data, and AH, HK, and HN interpreted the results and wrote the draft. MNa, YN, MNi, HO, YM, MK, TT, KS, KI, and MH interpreted the results, and critically reviewed and revised the manuscript. All authors have read and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The potential conflicts of interest for each author are as follows: HK received honoraria from Novartis. MNa’s spouse received honoraria (HN’s interests). YN received research funding from Astellas, Chugai, Novartis, and honoraria from Astellas, Kyowa Kirin, and Chugai. MNi received research funding from Astellas and Pfizer, and honoraria from Nippon Shinyaku, Otsuka, and Takeda. HO received research funding from Takeda, and honoraria from Nippon Shinyaku. TT received research funding from Pfizer, and honoraria from Chugai, Kyowa Kirin, Novartis, Takeda, and Sanofi. MH received research funding from Nippon Shinyaku; scholarship grants from Chugai, JCR Pharmaceuticals, Kyowa Kirin, Takeda, and Otsuka; and honoraria from Astellas, Chugai, Kyowa Kirin, Nippon Shinyaku, Novartis, Otsuka, Pfizer, Sanofi, and Takeda. HN received research funding from Astellas, Novartis, and Takeda, and honoraria from Astellas, Chugai, Nippon Shinyaku, Novartis, Otsuka, and Takeda. This study was not funded by any of these companies. The other authors declare no conflicts of interest associated with this manuscript.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hirose, A., Koh, H., Nakamae, M. et al. A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02231-4
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02231-4